CNR Institutional Research Information System

Montalto, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.876
NA - Nord America 1.106
EU - Europa 552
SA - Sud America 408
AF - Africa 33
OC - Oceania 2
Totale 3.977
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.054
SG - Singapore 881
CN - Cina 363
BR - Brasile 331
HK - Hong Kong 217
NL - Olanda 208
VN - Vietnam 185
FR - Francia 118
IT - Italia 91
KR - Corea 51
GB - Regno Unito 46
IN - India 38
JP - Giappone 38
AR - Argentina 36
BD - Bangladesh 21
CA - Canada 20
MX - Messico 18
ZA - Sudafrica 15
DE - Germania 13
FI - Finlandia 13
EC - Ecuador 12
IL - Israele 11
PL - Polonia 11
ID - Indonesia 10
RU - Federazione Russa 9
SA - Arabia Saudita 9
ES - Italia 8
IQ - Iraq 8
TR - Turchia 8
KE - Kenya 7
UY - Uruguay 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
CO - Colombia 5
LT - Lituania 5
PE - Perù 5
PK - Pakistan 5
VE - Venezuela 5
JM - Giamaica 4
OM - Oman 4
UA - Ucraina 4
AT - Austria 3
CZ - Repubblica Ceca 3
KH - Cambogia 3
KZ - Kazakistan 3
LV - Lettonia 3
PT - Portogallo 3
PY - Paraguay 3
SE - Svezia 3
AU - Australia 2
AZ - Azerbaigian 2
BB - Barbados 2
CH - Svizzera 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
MD - Moldavia 2
NP - Nepal 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
UZ - Uzbekistan 2
BS - Bahamas 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
GE - Georgia 1
GH - Ghana 1
HN - Honduras 1
IE - Irlanda 1
IS - Islanda 1
JO - Giordania 1
KG - Kirghizistan 1
LB - Libano 1
MA - Marocco 1
MG - Madagascar 1
PA - Panama 1
PS - Palestinian Territory 1
QA - Qatar 1
RE - Reunion 1
SI - Slovenia 1
TG - Togo 1
TW - Taiwan 1
Totale 3.977
Salva come PNG Salva come JPEG
Città #
Singapore 528
Santa Clara 447
Hong Kong 214
Hefei 125
San Jose 115
Lauterbourg 97
Beijing 68
Ashburn 65
Ho Chi Minh City 65
Seoul 50
Hanoi 43
Dallas 33
Los Angeles 33
Tokyo 29
São Paulo 20
Buffalo 14
New York 14
Atlanta 10
Chennai 10
Phoenix 10
Boardman 9
Helsinki 9
Manchester 9
Brasília 8
Brooklyn 8
Da Nang 8
Frankfurt am Main 8
Johannesburg 8
Minamishinagawa 8
Orem 8
Palermo 8
Warsaw 8
Bengaluru 7
Denver 7
Montreal 7
Mumbai 7
Nairobi 7
Rio de Janeiro 7
Salvador 7
Thái Bình 7
Belo Horizonte 6
Curitiba 6
City of London 5
Dhaka 5
Fortaleza 5
Guayaquil 5
Haiphong 5
Mexico City 5
Montevideo 5
Newark 5
Poplar 5
Porto Alegre 5
Shanghai 5
Ankara 4
Baghdad 4
Bắc Ninh 4
Chicago 4
Council Bluffs 4
Houston 4
Lappeenranta 4
Lima 4
London 4
Ninh Bình 4
Portsmouth 4
Riyadh 4
Seeb 4
Americana 3
Anápolis 3
Bogotá 3
Bologna 3
Bình Dương Province 3
Duque de Caxias 3
Elk Grove Village 3
Forest City 3
Goiânia 3
Gramado 3
Imperatriz 3
Marseille 3
Paris 3
Phnom Penh 3
Potenza 3
Prague 3
Quito 3
Recife 3
Riga 3
Santiago 3
Santos 3
St Petersburg 3
Stockholm 3
Uberlândia 3
Amsterdam 2
Aparecida de Goiânia 2
Aracaju 2
Baku 2
Barnet 2
Betim 2
Biên Hòa 2
Boa Vista 2
Bratislava 2
Buenos Aires 2
Totale 2.356
Salva come PNG Salva come JPEG
Nome #
The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods 97
Potential uses of olive oil secoiridoids for the prevention and treatment of cancer: A narrative review of preclinical studies 95
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells 91
Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation 84
New landscapes and horizons in hepatocellular carcinoma therapy. 82
The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH 68
Cancer therapy and treatments during COVID-19 era 62
COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer Cells. 61
RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma 61
Bergamot reduces plasma lipids, atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: A 6 months prospective study 59
NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response 56
Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells 53
Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines 52
Hepatocellular Carcinoma: A Difficult Cancer to Treat 52
GSK-3 in liver diseases: Friend or foe? 52
Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis 52
Aromatase and amphiregulin are correspondingly expressed in human liver cancer cells. 51
Abilities of ?-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells 51
Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy 50
Targeting GSK3 and Associated Signaling Pathways Involved in Cancer 49
The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment 49
Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis 48
Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma 48
Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling 47
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals 46
Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53 46
Emerging Use of Nanotechnology for the Treatment of Liver Diseases 45
Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma 44
GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals 43
Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals 42
Aromatase and amphiregulin are correspondingly espressed in human liver cancer cells. 40
Emerging Raf inhibitors. 40
Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma 40
Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells 40
Association Between MICA Gene Variants and the Risk of Hepatitis C Virus-Induced Hepatocellular Cancer in a Sicilian Population Sample 39
Non invasive tools for the diagnosis of liver cirrhosis 38
Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. 38
Association between single nucleotide polymorphisms in the cyclooxygenase-2, tumor necrosis factor-±, and vascular endothelial growth factor-A genes, and susceptibility to hepatocellular carcinoma. 37
Antitumor effects of DHMEQ, a novel NF-kB inhibitor, in human liver cancer cells is mediated through a reactive oxygen species-dependent mechanism. 36
Sex hormones and risk of liver tumor. 36
Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response. 35
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 34
Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response. 32
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells. 32
Potentiation of antitumor effects of NSAIDs by inhibition of MEK/ERK activity in human hepatocellular carcinoma cells. 31
The selective COX-1 inhibitor SC-560 inhibits cell growth and induces apoptosis in human hepatocellular carcinoma cells 31
Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells 30
Induction of apoptosis and inhibition of cells growth in human hepatocellular carcinoma cells by COX-2 inhibitors. 30
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: An 18-month prospective study 30
Altered gene expression profiles in liver cancer cells upon sorafenib treatment. 29
Targeting breast cancer initiating cells: Advances in breast cancer research and therapy. 29
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 29
A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells 29
Combination of DHMEQ and Celecoxib synergistically exert anti-tumoral effects in human hepatoma cells. 29
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells 28
The selective COX-1 inhibitor SC-560 inhibits cell growth and induces apoptosis in human hepatocellular carcinoma cells. 28
Micro-RNA signature of human hepatocellular carcinoma (HCC). 28
Significance of autologous Interleukin 6 production in the HA22T/VGH cell model of hepatocellular carcinoma. 28
Gene expression profiling of human liver cancer cells following celecoxib treatment. 28
Antitumor effects of the selective cyclooxygenase-1 inhibitor SC-560 is potentiated by inhibiton of MEK/ERK pathway in human hepatocellular carcinoma cells. 28
Cyclooxygenase-2 expression in chronic liver disease and hepatocellular carcinoma: an immunohistochemical study. 27
PAP/HIP Protein is an Obesogenic Factor 27
Critical Roles of EGFR family members in breast cancer and breast cancer stem cells: Targets for therapy 27
Influence of MEK/ERK signaling on apoptosis induced by selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatocellular carcinoma cells. 27
Induction of Apoptosis and Inhibition of Cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors 27
Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. 27
The novel NF-kB inhibitor DHMEQ suppresses the growth of human hepatic cancer cells through redox-dependent signaling. 27
Hepatic expression of cycloxygenase-2 in non-alcoholic fatty liver disease. 27
DHMEQ, a novel NF-kb inhibitor, anticancer activity through induction of reactive oxygen species-dependent mechanism in human hepatoma cells. 27
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways 27
Transcriptional regulation of micro-RNAs highly expressed in human HCCS 26
Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs 26
Circulating E-selectin levels in chronic hepatitis C patients with normal or elevated transaminase before and after alpha-interferon treatment. 26
Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle. 26
Inhibition of MEK/ERK pathway enhances apoptosis induced by selective COX-1 and COX-2 inhibitors in human hepatocellular carcinoma cells. 26
The multikinase inhibitor Sorafenib exhibits a strong cytotoxic effect in liver cancer cells through a MEK/ERK signaling-independent mechanism 26
Significance of autologous Interleukin 6 production in the HA22T/VGH cell model of hepatocellular carcinoma. 25
DHMEQ and Celecoxib synergistically exert anti-tumoral activities in human liver cancer cells. 25
Effects of Liraglutide on Carotid Intima-Media Thickness in Patients with Type-2 Diabetes and Non-Alcoholic Fatty Liver Disease: An 8-Month Prospective Pilot Study 25
IL-6 -174G®C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. 25
Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases 25
Inhibition of MEK/ERK pathway enhances apoptosis induced by selective COX-1 and COX-2 inhibitors in human hepatocellular carcinoma cells. 25
Altered gene expression profiles in liver cancer cells upon sorafenib treatment. 25
Cyclooxygenase-2, Tumor Necrosis Factor-±, Vascular Endothelial Growth factor-A and IL-6 genes SNPS and Il-6 serum levels in liver cirrhosis and hepatocellular carcinoma. 24
Targeting signaling pathways in prostate cancer 24
Sex hormones and risk of liver tumors 24
Cyclooxygenases in hepatocellular carcinoma. 24
Cyclooxygenase-2 expression in chronic liver disease and hepatocellular carcinoma: an immunohistochemical study. 23
The association of variants in PNPLA3 and GRP78 and the risk of developing hepatocellular carcinoma in an Italian population 23
Potentiation of antitumor effects of NSAIDs by inhibition of MEK/ERK activity in human hepatocellular carcinoma cells 23
Inhibition of GSK-3 beta activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in breast cancer 23
NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance. 23
Influence of MEK/ERK signaling on apoptosis induced by selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatocellular carcinoma cells 23
Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation 23
Transcriptional regulation of signature miRNAs 23
Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis 23
Roles of p53, NF-?B and the androgen receptor in controlling NGAL expression in prostate cancer cell lines 22
Hepatic expression of cycloxygenase-2 in non-alcoholic fatty liver disease. 22
The selective COX-1 inhibitor SC-560 suppresses cell growth and induces apoptosis in human hepatocellular carcinoma cells. 21
Management of liver failure: from transplantation to cell-based therapy. 21
Totale 3.708
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.186
article - articoli 9.396
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 143
Totale 22.725
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20248 0 0 0 0 0 0 0 0 0 0 3 5
2024/20251.695 16 8 111 61 386 73 29 56 40 214 393 308
2025/20262.285 87 199 229 443 420 79 332 130 145 127 94 0
Totale 3.988